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GWAS of mosaic loss of chromosome Y highlights
genetic effects on blood cell differentiation
Chikashi Terao 1,2,3*, Yukihide Momozawa4, Kazuyoshi Ishigaki1, Eiryo Kawakami5,6,7, Masato Akiyama1,8,
Po-Ru Loh 9,10, Giulio Genovese10,11,12, Hiroki Sugishita13, Tazro Ohta 14, Makoto Hirata 15,
John R.B. Perry16, Koichi Matsuda 15,17, Yoshinori Murakami 18, Michiaki Kubo4 & Yoichiro Kamatani 1,19*
Mosaic loss of chromosome Y (mLOY) is frequently observed in the leukocytes of ageing
men. However, the genetic architecture and biological mechanisms underlying mLOY are not
fully understood. In a cohort of 95,380 Japanese men, we identify 50 independent genetic
markers in 46 loci associated with mLOY at a genome-wide significant level, 35 of which are
unreported. Lead markers overlap enhancer marks in hematopoietic stem cells (HSCs, P≤
1.0 × 10−6). mLOY genome-wide association study signals exhibit polygenic architecture and
demonstrate strong heritability enrichment in regions surrounding genes specifically
expressed in multipotent progenitor (MPP) cells and HSCs (P≤ 3.5 × 10−6). ChIP-seq data
demonstrate that binding sites of FLI1, a fate-determining factor promoting HSC differ-
entiation into platelets rather than red blood cells (RBCs), show a strong heritability
enrichment (P= 1.5 × 10−6). Consistent with these findings, platelet and RBC counts are
positively and negatively associated with mLOY, respectively. Collectively, our observations
improve our understanding of the mechanisms underlying mLOY.
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Mosaic loss of chromosome Y (mLOY)
1 is characterized
by the presence of cells that have lost chromosome Y.
mLOY is well described in samples from the bone
marrow2 and can also be detected in peripheral blood cells3. Age4
and smoking5 are well established risk factors for mLOY, how-
ever, the broader mechanisms that influence mLOY, including the
stage(s) of hematopoietic differentiation during which mLOY
arises, are not fully known. Genetic analysis can provide biolo-
gical insight into the basis of this phenomenon. The same array-
based assays can provide information about single-nucleotide
polymorphism (SNP) genotype and, from intensity data of
genome-wide probes, allow inference of mosaic events6,7. This
has allowed previous studies to identify some genetic determi-
nants underlying mLOY. Zhou et al. reported that mLOY is
associated with a variant in the TCL1A gene locus8. Wright et al.
identified a total of 19 loci associated with mLOY9, including
TCL1A and other genes involved in cell cycle regulation and
DNA damage response. Previous studies examined European
populations, so genetic studies from an East Asian population
would expand our knowledge of the genetic architecture under-
lying mLOY, in turn allowing us to make deeper biological
inferences about mLOY based on expanded genetic findings.
The clinical significance of mLOY is still unclear10. Previous
studies reported that mLOY is associated with shorter life span
and increased risk for cancer onset3,11,12. Other studies suggested
that mLOY is associated with onset of acute myeloid leukemia
(AML) or other hematological disorders13,14. However, Zhou
et al. did not find significant differences in overall survival or
cancer-specific survival in data from 5340 cancer cases8. No
studies have analyzed the clinical significance of mLOY in Asian
populations. Although the clinical significance of mLOY is not
well established, clarifying the mechanisms of chromosome loss
may provide a deeper understanding of clonal expansion during
hematopoiesis, cellular ageing, and cancer development. Fur-
thermore, there is a possibility that mLOY has a distinct clinical
impact in Asian populations.
Here, we use genotype array data from 95,380 Japanese males
enrolled in the Biobank Japan Project (BBJ) to study mLOY15.
We examine the genetic architecture of mLOY, performing the
genome-wide association study (GWAS) of this condition in an
East Asian population. To infer biological mechanisms driving
mLOY, we conduct downstream analyses using our GWAS
results, making inferences based on overlap of associated variants
and polygenic mLOY heritibility with functional elements to
pinpoint the cell types and gene pathways involved in mLOY.
Furthermore, we conduct association studies between mLOY and
survival data of the participants to evaluate the clinical sig-
nificance of mLOY in an Asian population.
Results
Estimation of mLOY from probe intensity data of DNA
microarray. The data were generated in three separate batches
due to advances in genotyping platforms during data collection.
Detailed description of the samples is shown in Supplementary
Table 1.
We applied a method similar to that used in Wright et al.9 to
estimate mLOY in our data. We obtained logarithm of R ratio
(LRR) probe intensity data across more than 1100 variants
(depending on batch) in chromosome Y for each male subject.
We used mean LRR (mLRR-Y) as a proxy for mean Y
chromosome dosage in circulating blood cells of subjects (for
details, see the Methods section). Hereafter, we use the term
‘mLOY GWAS’ to denote GWAS on mLRR-Y, as in Wright
et al.9.
Associations between mLOY and age or smoking. We observed
a strong association between age at DNA collection and mLOY (1
year increase in age associated with 2.2% standard deviation (SD)
decrease in mLRR-Y signal, P < 1.0 × 10−100, Wald test in linear
regression analysis, Fig. 1a; Supplementary Fig. 1) explaining
9.6% of the variance in mLOY. We also observed a significant
association between smoking and mLOY (Supplementary Fig. 2);
smokers often have lower mean intensity of chromosome Y
probes, indicating a higher fraction of cells with loss of chro-
mosome Y (smokers associated with 4.6% SD decrease in mLRR-
Y signal, P= 7.5 × 10−10, Wald test in linear regression analysis).
These associations are in agreement with previous studies5.
mLOY as a highly polygenic trait. Next, we imputed genotypes
using genotyping array data after standard quality control
(Methods) and a reference panel of whole-genome
sequenced individuals, including 2504 individuals from the
1000 Genomes project phase 3 and 1,037 Japanese16,17 (Methods
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Fig. 1 Associations of Chromosome Y signals with old age and a total of 50 genetic determinants in mLOY. a An association between mLOY and age at
blood collection is indicated. We do not show outliers in the figure. Bars indicate the most extreme data points which are no more than 1.5 times
interquartile ranges from the boxes. b Polygenetic architecture in mLOY. Mean chi-square statistics and LD scores in 100 bins of Hapmap project variants
in mLOY are indicated. Bins are made according to LD scores to contain almost equal number of variants in each bin. c Manhattan plot of mLOY in this
study. Green and red colors indicate previously reported and unreported regions, respectively. Only P-values >1.0 × 10−30 are shown
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and Supplementary Note 1). We conducted a Bayesian mixed-
model association study to identify mLOY susceptibility loci,
controlling for age, smoking, genotyping batch, and disease status
(for details, see the Methods section).
We found strong evidence for polygenicity of mLOY GWAS
signals. Chi-squared statistics for association with mLOY deviated
slightly from expected statistics in a quantile–quantile plot
(lambda= 1.066, Supplementary Fig. 3). We evaluated polygenic
effects on mLOY using linkage disequilibrium (LD) score
regression18, with the use of ldsc software. This regression
analysis suggested that mLOY is a highly polygenic trait and that
departure of mean chi-squared statistics could be largely
explained by polygenic effects (lambda genomic control 1.086 >
intercept 1.019 in ldsc, Fig. 1b and Supplementary Note 2). Since
LD score regression revealed minimal bias, we did not correct
study statistics by genomic control19.
Common genetic architecture of mLOY with Europeans. To
understand our results in the context of what is known about the
genetics of mLOY in Europeans, we compared our results to
previous analyses. We found a total of 46 loci significantly
associated with mLOY, 15 of which were reported by Wright
et al.9 from analysis of data from the UK BioBank (Fig. 1c,
Tables 1, 2; Supplementary Fig. 4). We found a consistent asso-
ciation trend (direction of effect of minor alleles) across all three
batches for each of the 46 associated variants (Supplementary
Table 2). Conditional analyses revealed that four loci, all of which
were among those found in Wright et al.9, contained two pre-
viously undetected independent signals (Table 3; Supplementary
Fig. 5). The 50 independent variants over 46 loci explained 3.2%
of mLOY variance, 1.6% of which could be explained by the 35
new variants. We estimated SNP-heritability of mLOY to be 9.3%
(see the Methods section).
We did not find significant associations in 4 of the 19 regions
identified by Wright et al.9 (Supplementary Fig. 6). The most
strongly associated variant (rs17758695) in the BCL2 gene locus,
the top locus identified by Wright et al.9, is not polymorphic in
the Japanese population (Supplementary Table 3). The top
variants in the other three regions identified by Wright et al.9, but
not here, were also very rare or not polymorphic in the Japanese
population (Supplementary Table 3). Therefore relative invar-
iance at these four loci in the Japanese population precludes
identification of a statistically significant signal in this population.
To further assess similarities and differences in the genetic
architecture of mLOY across populations, we examined associa-
tions of the 46 loci with mLOY in 205 thousand male participants
in the full UK Biobank release (Supplementary Table 4). Thirty-
nine of the 46 top variants were polymorphic, and had minor
allele frequencies (MAF) >0.5% in the UK population. Thirty-
seven of these 39 variants had the same effect direction in UK
Biobank and BBJ (P= 2.8 × 10−9, binomial test). When con-
sidering only the 31 novel loci, this trend remained consistent;
twenty-five variants were polymorphic and had MAF >0.5% in
the UK population, and 23 out of the 25 variants had the same
effect direction in the two studies (P= 1.9 × 10−5, binomial test),
indicating strong genetic overlap in association with mLOY
between the two populations.
Involvement of hematopoietic stem cells with mLOY. In order
to assess the cell types important for mLOY based on significant
GWAS signals, we next analyzed the 46 lead variants in BBJ for
overlap with cell-type-specific enhancer marks using Haploreg20.
Table 1 A total of 31 previously unreported significant loci in mLOY
SNP Chr BP Gene A0 A1 A1frq Beta P
rs34468831 1 3097312 PRDM16 GA G 0.37 −0.032 3 × 10−12
rs527504 1 33392427 TMEM54;RNF19B G A 0.19 −0.032 4.1 × 10−9
rs17049722 2 58976863 LINC01122 C T 0.17 0.038 4.4 × 10−12
2: 136879065 2 136879065 CXCR4 G ALU 0.32 −0.035 9.3 × 10−13
rs34778241 3 71771215 EIF4E3 T TG 0.71 −0.030 2.1 × 10−9
rs2811487 3 128331879 LINC01565;RPN1 G A 0.36 0.027 6.8 × 10−10
rs871134 4 7044380 CCDC96 C T 0.49 −0.032 1.4 × 10−14
rs2853677 5 1287194 TERT G A 0.70 0.027 2.1 × 10−9
rs10948011 6 42024285 TAF8 G A 0.23 0.035 4 × 10−12
rs35355140 7 27204732 HOXA9 C A 0.14 0.045 2.3 × 10−13
rs11769630 7 50257703 C7orf72;IKZF1 T A 0.13 −0.057 3.7 × 10−19
rs59543286 7 135351310 C7orf73 A C 0.23 0.059 8 × 10−32
rs55727837 7 149428602 KRBA1 G T 0.11 0.061 9.7 × 10−20
rs12668837 7 158500805 NCAPG2;ESYT2 C T 0.46 −0.026 1.8 × 10−9
rs189309686 8 59509355 NSMAF C T 0.25 0.027 4.4 × 10−8
rs10692222 8 130597362 CCDC26 C CATT 0.43 0.025 6 × 10−9
rs2804301 9 603916 KANK1 G A 0.24 −0.027 4.4 × 10−8
rs9299129 9 109638167 ZNF462 A G 0.23 0.030 2.2 × 10−9
rs138423884 9 129855937 ANGPTL2;RALGPS1 A G 0.038 0.079 1.3 × 10−12
rs2646425 10 8470387 LINC00708;LOC105376398 C T 0.31 0.028 4.3 × 10−10
rs12225799 11 241124 PSMD13 C G 0.13 −0.036 1.1 × 10−8
rs2237896 11 2858440 KCNQ1 G A 0.40 0.043 1.7 × 10−22
rs74843651 11 14292987 SPON1;RRAS2 G T 0.052 0.055 2.2 × 10−8
rs10849448 12 6493351 LTBR A G 0.81 −0.050 1.5 × 10−18
rs34324 12 12877926 APOLD1 C A 0.43 −0.039 3.1 × 10−19
rs548509555 13 57601900 MIR5007;PRR20B T TA 0.20 0.032 8.1 × 10−9
rs9921295 16 50027130 ZNF423;CNEP1R1 T G 0.33 0.031 4 × 10−12
rs1859259 16 57596552 GPR114 C T 0.58 −0.025 1.1 × 10−9
rs77406149 17 53076247 STXBP4 A G 0.20 0.035 2.5 × 10−10
rs79058858 19 49979789 FLT3LG C T 0.0052 0.16 1.4 × 10−8
rs117587217 21 16631171 NRIP1;USP25 T C 0.016 −0.10 9.7 × 10−9
Chr chromosome, BP base pair position in NCBI build 37, Gene italicized gene name, A1frq A1 allele frequency, Beta A1 allele beta
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We found a strong overlap between the variants and enhancer
marks present in hematopoietic stem cells (HSCs) (Fig. 2; Sup-
plementary Table 5). This finding is in line with the theory that
clonal expansion of HSCs lacking chromosome Y underlies
mLOY, as has been shown for clonal hematopoiesis of HSCs
bearing a point mutation21. The 31 new loci found in the current
study accounted for this overlap. Two completely independent
sets of variants (31 and 19 loci in Japan and UK, respectively)
showed overlap with enhancer marks in HSCs (Supplementary
Fig. 7). Enhancer marks in embryonic stem cells (ES cells) or
induced pluripotent stem cells (iPS cells), both of which can
differentiate into HSCs22, did not strongly overlap with mLOY
GWAS significant signals. Thus the variants associated with
mLOY overlap with cell type-specific epigenetic features emer-
ging after differentiation into hematopoietic cells, rather than
epigenetic features characterizing pluripotency itself.
To further infer the functional implications of our genetic
results regarding mLOY, we next analyzed the polygenic
architecture of mLOY, not restricting to GWAS significant
signals. We partitioned heritability of mLOY according to
functional annotations23 using ldsc (see the Methods section).
Superenhancer, H3K27ac, and transcription start site (TSS) were
the top three categories with positive and significant heritability
enrichment (>2.5-fold enrichment, P ≤ 3.1 × 10−6, Supplementary
Table 6), suggesting that gene expression regulation, especially by
superenhancers, is involved in the mechanisms underlying
mLOY. Deep involvement of superenhancers with gene expres-
sion regulation may characterize mLOY genetic architecture,
considering low enrichment of superenhancers in other traits’
heritability23. We next conducted cell-group-specific heritability
enrichment analysis using ldsc. This revealed that mLOY
heritability was highly enriched in histone marks associated with
the hematopoietic cell group (Fig. 3a). We next used ldsc to
further analyze whether histone marks enriched in specific
hematopoietic cell types, among a total of 220 cell types, could
explain the heritability of mLOY. We found that histone marks
specific for CD34-positive cells (HSCs and hematopoietic
progenitor cells) showed the strongest heritability enrichment
(Fig. 3b; Supplementary Table 7). The mLOY heritability
enrichment in superenhancers, histone marks in the hemato-
poietic cell group, and CD34-positive cells were confirmed in the
analyses with ldsc where we used different baseline annotations
Table 2 Significant signals in the 15 known loci
SNP Chr BP Gene A0 A1 A1frq Beta P
rs2842873 1 156204653 PMF1;PMF1-BGLAP C T 0.37 −0.056 1.5 × 10−36
rs4683900 3 101134696 SENP7 C T 0.73 0.042 7.9 × 10−19
rs4681200 3 150002138 LINC01214 C G 0.92 0.072 3.8 × 10−19
rs56116444 5 111061847 STARD4-AS1 T G 0.31 −0.086 9.2 × 10−81
rs11251 6 109689907 CD164 G T 0.54 0.028 3.4 × 10−11
rs4709819 6 164463355 LOC102724152;MEAT6 G A 0.41 0.049 1.3 × 10−30
rs4721217 7 1973579 MAD1L1 C T 0.42 −0.043 6.8 × 10−23
rs2979469 8 30285091 RBPMS G C 0.88 −0.035 4.9 × 10−8
rs227079 11 108248686 C11orf65 C A 0.48 −0.044 5.9 × 10−26
rs728739 14 96182062 TCL1A;TUNAR A G 0.055 0.081 3.8 × 10−18
rs72698721 14 101181189 LINC00523;DLK1 G A 0.32 0.055 4.2 × 10−33
rs77874075 16 81066339 CENPN T G 0.22 −0.030 4.6 × 10−9
rs201753350 17 7579705 TP53 C T 0.0062 −0.15 1 × 10−8
rs78997619 17 47787161 FAM117A C T 0.060 0.083 2.5 × 10−21
rs80277818 18 42017901 LINC01478 A G 0.26 −0.075 7.8 × 10−55
Chr chromosome, BP base pair position in NCBI build 37, Gene italicized gene name, A1frq A1 allele frequency, Beta A1 allele beta
Table 3 Secondary signals in the four known loci
SNP Chr BP Gene A0 A1 A1frq Beta P
rs9487023 6 109590004 C6orf183 G A 0.10 0.040 3.5 × 10−8
rs4251697 12 12874462 CDKN1B A G 0.081 0.059 1.5 × 10−10
rs139012944 14 96180705 TCL1A T C 0.071 −0.051 3.8 × 10−8
rs8088824 18 42151261 LINC01601;SETBP1 T C 0.82 −0.056 3.4 × 10−23
Chr chromosome, BP base pair position in NCBI build 37, Gene italicized gene name, A1frq A1 allele frequency, Beta A1 allele beta
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Fig. 2 Significant variants in mLOY showing enrichment of enhancer marks
in CD34+ HSCs. The results of enhancer enrichment of mLOY 46 top
markers in 127 cell types calculated by Haploreg are indicated. Cell groups
are shown in different colors. The results are sorted by cell groups and
P-values. The horizontal solid line indicates significant level of P-value
based on Bonferroni’s correction (empirical P= 0.000394 (0.05/127))
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recently proposed to take into consideration difference in LD
pattern of variants, information of synonymous/nonsynonymous
coding variants, sequence age and conservation of variants across
species24 (see Methods and Supplementary Note 3). Taken
together, both genome-wide significant loci and polygenic signals
suggested involvement of CD34-positive cells with mLOY.
Heritability enrichment in hematopoietic progenitor cells.
CD34 is expressed in hematopoietic progenitor cells, which include
multipotent progenitor (MPP) and common myeloid progenitor
(CMP), as well as HSC25. Therefore, to understand which differ-
entiation stages are important for developing mLOY, we analyzed
enrichment of mLOY heritability in chromatin regions that are
open in various hematopoietic progenitor cells and lineages. We
analyzed the GWAS results of mLOY with ldsc applied to specifi-
cally expressed genes (LDSC-SEG) using ATAC-seq data of
hematopoietic progenitor cells and lineages at different differ-
entiation stages26. Genes expressed in MPP and HSC, evidenced by
open-chromatin state assessed by ATAC-seq, showed the strongest
and the 2nd strongest heritability enrichment with mLOY,
respectively (Fig. 3c; Supplementary Table 8 and Supplementary
Note 3). We found decreasing heritability enrichment in genes
expressed at subsequent differentiation stages; the further differ-
entiated the cell type was from HSC and MPP, the less enrichment
was observed. These results suggest that not only HSC but also
MPP may be important differentiation stages at which genetic
factors influence the development of mLOY.
Enriched heritability in transcription factor binding sites.
Previous studies have revealed that transcription factors (TFs) play
a critical role in hematopoietic cell differentiation and function27.
Thus, we hypothesized that overlap of genetic associations with
TF-binding sites in various hematopoietic cells may provide
information about lineage- or context-specific influence on mLOY.
We used available chromatin immunoprecipitation sequencing
(ChIP-seq) data to help identify TFs involved in mLOY. We
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obtained a total of 37 ChIP-seq data sets derived from CD34-
positive cells or HSCs (for details, see the Methods section).
Binding sites of three transcription factors, namely, FLI1, GATA2,
and RUNX1, showed significant overlap with regions positively
enriched in mLOY heritability (P ≤ 4.0 × 10−4, Fig. 3d). GATA2
and RUNX1 are TFs critical for HSC and hematopoiesis28,29,
supporting the findings above. We focused on binding sites of
FLI1, a TF important for megakaryocyte differentiation30, which
showed the strongest heritability enrichment (P= 1.5 × 10−6, P-
value for enrichment, and Supplementary Note 3). Binding sites of
FLI1 that associated with mLOY heritability were independent
from those of GATA2 and RUNX1 (P= 4.1 × 10−4, P-value for
enrichment). Heritability enrichment in FLI1-binding sites was not
seen in the 11 other cell types for which FLI1 ChIP-seq data were
available, supporting the biological specificity of this result; herit-
ability of mLOY is enriched in binding sites of FLI1 in CD34-
positive cells (Supplementary Fig. 8). We searched for possible
enrichment of mLOY heritability in TF-binding sites for any cell
type. Notably, the FLI1-binding sites in CD34-positive cells showed
the strongest heritability enrichment across all 2861 TF-cell type
pairs available (see the Methods section and Supplementary Fig. 9).
Among megakaryocyte/erythrocyte progenitors (MEP), common
lymphoid progenitors (CLP) and granulocyte/macrophage pro-
genitors (GMP) (which are similarly differentiated and lineage-
committed progenitors, Fig. 3c), the highest heritability enrichment
in expressed genes was observed for MEP. This is broadly con-
sistent with heritability enrichment in binding sites of FLI1, which
is critical for differentiation of MEP31. Importantly, ES cells and
iPSC, which have potential to differentiate to HSCs, did not show
strong heritability enrichment in TF-binding sites (357 ChIP-seq
data, P > 0.05/357, P-value for enrichment, Supplementary Fig. 10),
emphasizing that interactions in the nucleus of HSCs or hemato-
poietic progenitor cells which appear after differentiation to the
hematopoietic lineage are important for mLOY.
Associations between hematopoietic traits and mLOY. FLI1
drives MEP31 to develop into megakaryocytes and thus produce
platelets rather than erythrocytes32,33. Therefore, we analyzed the
association between mLOY and hematologic traits (including
platelet count and red blood cell (RBC) count) using data from
57,987 subjects from whom complete blood counts (CBC) were
available at the time of DNA collection. mLOY was positively
associated with platelet count (i.e., higher platelet count, lower
mLRR-Y, and higher mLOY; 1 SD increase in platelet count
(66,000/ul) associated with 0.03 SD decrease in mLRR-Y signal, P
= 7.6 × 10−14, Wald test in linear regression analysis) and WBC
count (P= 4.2 × 10−15, Wald test in linear regression analysis,
Supplementary Fig. 11). In contrast, we observed a nonsignificant
negative association with RBC count (i.e., higher RBC count,
higher mLRR-Y, and lower mLOY, Supplementary Fig. 11). The
effect size of platelet count (and RBC) on mLOY was enhanced in
individuals estimated to have a high fraction of cells with loss of
chromosome Y (Fig. 3e).
These results are compatible with significant heritability
enrichment in FLI1-binding sites. Since RUNX1 also regulates
maturation of megakaryocytes and represses erythrocyte gene
expression during megakaryocytic differentiation34, these results
also support significant heritability enrichment of RUNX1
binding sites. We did not find significant genetic correlations
between mLOY and platelet or RBC counts (Supplementary
Table 9 and Supplementary Note 4). This suggests that the
association between mLOY and platelet count may be derived
from limited genetic components (likely including FLI1 and
RUNX1) rather than from diverse polygenic effects or from
shared nongenetic factors.
Pathway analysis and Mendelian randomization of mLOY. Our
results so far suggest that the genetic variants and polygenic
associations of mLOY mostly overlap with functional elements
in specific hematopoietic progenitor cells. However, the specific
cellular pathways and gene-regulatory networks involved in
mLOY remain uncertain. To address this, we conducted path-
way analysis using PASCAL software35 and genetic correlation
analyses with other quantitative and qualitative traits (see
Methods). PASCAL takes not only GWAS significant loci but
whole-genome signals into consideration. We found that gene
scores calculated based on the GWAS signal of mLOY showed
the strongest and most significant enrichment in cell cycle
pathways and a mitotic pathway (Supplementary Table 10).
This is compatible with the partial overlap of mLOY suscept-
ibility genes and oncogenes9 as well as with the hypothesis that
mitotic clonal expansion of an HSC lacking chromosome Y
underlies lower mLRR-Y values. We also conducted genetic
correlation analyses between mLOY and quantitative traits or
malignancies with which we previously reported genetic asso-
ciations36. We observed a significant genetic correlation
between mLOY and aspartate transaminase (AST) (Supple-
mentary Fig. 12 and Supplementary Table 9). A bidirectional
Mendelian randomization (MR) approach suggests a causal
effect of mLOY on increase of AST (P= 0.037, Supplementary
Note 4).
Associations between mLOY and clinical outcomes. Finally, we
investigated the clinical significance of mLOY. We analyzed
survival and mLOY in 54,887 BBJ participants followed at a
maximum of 12 years after registry37 (for details, see Methods).
There was no association between mLOY and overall survival
(Fig. 4a). A previous study that found an association
between mLOY and decreased survival used a different
analytic approach, one which is strongly influenced by the
small number of subjects who have a high fraction of cells
lacking chromosome Y (Supplementary Note 5)3. Therefore,
we tested whether subjects with a high fraction of cells lacking
chromosome Y have adverse outcomes in the studied
cohort. We found that subjects with lower mLRR-Y values
(indicating a higher fraction of cells lacking chromosome Y)
were more likely to have experienced an adverse outcome
(Supplementary Fig. 13), which seems compatible with the
previous finding3.
Genome instability, including chromosome rearrangements
and loss, is a central event in development of some cancers, so
genetic determinants that increase susceptibility to mLOY may
influence cancer risk. We therefore analyzed whether the
associations between mLRR-Y and mortality were mediated by
malignances. We found a significant association between mLOY
and death due to lung cancer (P= 0.0010, Cox proportional
hazards regression, Hazard ratio 1.09 (95% CI: 1.04–1.15), Fig. 4b)
after conditioning on covariates, including smoking. Subjects with
a high fraction of mLOY consistently showed associations with
death of lung cancer (Supplementary Fig. 14). However, we found
that the association between mLOY and lung cancer was mostly
contributed by individuals with a smoking history; the con-
founding effect of smoking on both lung cancer and mLOY is
difficult to disentangle even conditioning on this covariate. When
we extracted and analyzed subjects with detailed smoking
information including smoking duration and quantity (at the
expense of decreasing sample size), the effect size of mLOY on
lung cancer was decreased, and the association was no longer
significant (Supplementary Note 6). We did not find significant
associations between mLOY and other cancer types or with all
malignancies (Fig. 4b).
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Discussion
This is a large study to analyze mLOY in a non-European
population. In accordance with the large study of mLOY in
Europeans (Wright et al.9), we used the mean of LRR as a proxy
of chromosome Y copy number. Using the mean, rather than the
median, of LRR allows that some strongly deviated markers could
unduly influence estimation of chromosome Y dosage. However,
we found that the median and mean are strongly correlated
(Spearman’s rho: 0.993) and lead to quite similar genetic asso-
ciation results (median LRR identifies 44 of the 46 loci identified
using mean, Supplementary Note 7). The minimal difference in
the two indices supports the rationale to use the method applied
in this study.
Our analyses provide insights into the mechanisms underlying
mLOY, suggesting that MPP and HSC are likely the primary cell
types undergoing of clonal expansion after loss of chromosome Y.
Genes expressed in hematopoietic lineages, especially HSC and
MPP, seem to be critical for mLOY development. As our results
suggest variants overlapping myeloid precursor functional regions
are involved in the development of mLOY, it would be interesting
to analyze subgroups of WBC in elderly populations to identify if
myeloid populations contain more cells lacking chromosome Y
than co-circulating lymphoid cells.
It is of note that while mLOY was detected by assessing
nucleated leukocytes, platelet and RBC counts were associated
with mLOY. The involvement was also supported by heritability
enrichment of FLI1 and GATA2 bindings. This indicates that
the molecular and cellular mechanisms underlying mLOY act
before cell fate is restricted to certain terminally differentiated
nucleated WBC types, in line with the importance of MPP and
HSC shown by enrichment analyses of GWAS significant signals
and polygenic signals. The association between WBC counts and
mLOY in a nondose dependent manner may reflect higher
chance to detect mLOY signals from probe intensity in subjects
having more WBC.
Genetic correlation between AST and mLOY and the result of
MR suggested a causal relationship between mLOY and increased
AST (more mLOY leading to higher AST). Since recent studies
have revealed that mosaic events frequently occur systemically38,
this may suggest that mLOY also occurs in the liver and affects
susceptibility to liver damage. It is of note that we did not observe
an association between mLOY and ALT. This suggests that
increase in AST level or ratio of AST and ALT in elderly popu-
lations could serve as a marker of mLOY. Especially given the
cell-type specificity of the genetic factors we identified, deter-
mining the genetic landscape of mLOY in other tissues including
the liver would be interesting.
Our study also analyzed association between mLOY and sur-
vival at an unprecedented scale. While we could replicate a trend
of poor outcome in subjects with a high burden of mLOY, the
clinical significance of mLOY was not very apparent in our study.
Since this is a large study to analyze effects of mLOY on clinical
outcomes in an Asian population, it is possible that the clinical
significance of mLOY is not the same across all populations.
However, it is also possible that mLOY is associated with onset of
specific types of cancer and/or context-dependent survival, such
as poor outcome in specific diseases, which could not be fully
captured by our population cohort.
While different LD structure between Japanese and UK
population made it difficult to quantify genetic similarities of
mLOY between the two populations, we showed that significant
variants found in the BBJ very often shared direction of effect on
mLOY in the UKB. We tried to replicate 156 significant variants
found in UKB, as a result, 92 out of the 100 variants which were
polymorphic and passed QC showed shared direction in effect39,
suggesting the strong overlap of susceptibility loci for mLOY
between the two populations. Considering common genetic
background of mLOY, susceptibility loci which are found sig-
nificant only in one population suggest that the causal variants in
these loci are polymorphic only in that population. In addition,
taking advantage of genetic overlap seemed to help us to pinpoint
shared causal variants of susceptibility loci.
Further in-depth analysis including trans-ethnic meta-ana-
lysis could reveal additional genetic components and context-
specific clinical significance of mLOY. Because we showed
mLOY shares genetic architecture across populations, trans-
ethnic meta-analysis would be attractive to increase the number
of associated loci and to obtain further biological insights from
finer resolution functional inference. The association between
mLOY and clinical outcomes should be replicated to resolve the
clinical impacts of mLOY and develop management protocols
for elderly populations. Disease-specific associations of mLOY
should be analyzed in disease-specific data sets rather than
population cohorts.
All_malignancy
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Fig. 4 Inference of clinical significance of mLOY. a Associations between overall mortality and signals of mLOY. b Associations between signals of mLOY
and mortality due to malignancy and organ-specific malignancy. Signals of mLOY are multiplied by −1 of normalized LRR (the lower LRR indicating large
fraction of mLOY, the higher signals are). Thus, beta exceeding 0 and hazard ratio exceeding 1 indicate associations between poor outcome (increased
mortality) and lower intensity (more mosaic). Width of diamonds indicates 95% confidence interval. All results are obtained in Cox proportional hazard
models. *indicates significant associations beyond Bonferroni’s correction
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Methods
Subjects and genotype data. We used 183,899 subjects in the BBJ project for
selection of samples to analyze for this study. Written informed consent was
obtained from all the participants. The study was approved by the ethical committees
in the Institute of Medical Science, the University of Tokyo and RIKEN Center for
Integrative Medical Science. Most of the subjects had already been genotyped using
genome-wide genotyping arrays40. In this study, we used genotype data from three
different sets using four different arrays, namely, (1) HumanOmniExpressExome
v1.0, (2) HumanOmniExpressExome v1.2, and (3) a combination of Illumina
HumanOmniExpress v1.0 and Human Exome v1.0 or v1.1 BeadChips. A breakdown
of the subjects and arrays is given in Supplementary Table 1.
Estimation of mLOY. Using log-R ratio (LRR) generated by Illumina GenomeS-
tudio software, mean LRR in Y chromosome (mLRR-Y) was calculated and used as
a proxy of mLOY as follows. We extracted only male subjects and reclustered the
subjects based on their probe signal intensities in variants on chromosome Y. This
step was performed separately for each type of array. We did not use intensity data
of Human Exome BeadChip to avoid batch effects within the same subjects. We
obtained LRR for all variants on chromosome Y excluding the pseudoautosomal
regions, and subjects and variants with missing rate higher than 5% (restricted to
the Y chromosome) were excluded from mLRR-Y calculation. As a result, 1268,
1305, and 1162 variants remained for calculation of mLRR-Y in the three batches
described above, respectively. We set LRR in variants with missing genotypes as
missing. We then standardized LRR in each variant, and calculated mean of LRR in
each subject across variants on chromosome Y. The mLRR-Y was standardized per
batch and used as a signal reflecting mLOY in the subjects. We took this approach
to avoid strong influence of limited number of variants with extreme values of LRR.
To confirm that our data did not suffer from noise due to variants with extreme
LRR, we also took median of LRR signals in each individuals among the variants
and conducted GWAS with the use of median LRR instead of mLRR-Y.
Quality control of subjects and SNPs. We excluded subjects found to be
genetically identical to other subjects (321 samples), showing discrepancy between
reported sex and inferred sex based on genotypes of variants on X chromosome
(1245 samples), found to be outliers from the EAS (Japanese and Chinese) cluster
(121 samples) in the analysis where we merged GWAS data with 1000 Genomes
Project genotype data, pruned variants by excluding variants in moderate LD with
other variants (with cutoff level of r2 of 0.5) and conducted principal component
(PC) analysis to project subjects in PC1 and PC2 space, included in the reference
panel mentioned below (939 samples) or showing a missing rate higher than 2%
(0 sample at this stage). Finally, we obtained data of 95,380 males whose probe
intensity data in the Y chromosome was available for subsequent analyses. SNPs with
missing rates more than 1%, Hardy–Weinberg equilibrium P-values <1.0 × 10−6 or
heterozygote calls <5 in each of the three arrays were excluded.
Whole-genome imputation. All genome-scanned samples were merged before
phasing and whole-genome imputation was conducted using a reference panel
which was produced by combining genotype data from 2504 subjects from the
1000 Genomes project41 and whole-genome sequence data (x30) of 1037 Japanese
subjects16 (see for detail, Supplementary Note 1). Eagle42 and Minimach343 soft-
wares were used for phasing and imputation, respectively.
Genome-wide association study. After whole-genome imputation, we tested
9,591,901 variants with squared Pearson correlation (r2) >0.3 (to ensure imputation
accuracy) and minor allele frequency >0.005 for association with mLOY. We
applied the Bayesian mixed-model using bolt-lmm44 (URL). Age, arrays, smoking,
and disease status (prevalence >0.5% in the subjects) were included as covariates
(Supplementary Table 11 and Supplementary Note 8). Since we used mixed model
taking into account genetic correlation matrix among subjects, we did not include
principal components in the covariates. The mean of smoking status was used for
subjects with missing information. P-values of 5.0 × 10−8 was set as genome-wide
significant level.
Variance and heritability estimation of mLOY. We calculated variance explained
by variants by the following formula:
Varexplained ¼ 2 ´E2 ´ af ´ 1 afð Þ ´Vartot1
where Var_explained indicates variance explained by a SNP, E indicates beta in
LMM, af indicates allele frequency of tested allele, and Var_tot indicates variance of
mLOY (we set to 1 by data standardization).
We used bolt-lmm software to evaluate heritability of mLOY. Briefly, bolt
calculates heritability of model SNPs (in this case, we provided genotyping array
data) by restricted maximum likelihood estimation (REML) to compute variance of
genetic components.
Independent signals in a single locus. Two associated loci on the same chro-
mosome were regarded as different if a genome-wide significant marker at one
locus was at least 1 Mbp apart from those in the other locus. This definition was
also applied to regard significant loci in the BBJ as the same as or different from
those described by Wright et al.9. We conducted conditional analyses to confirm
that two loci were independently associated with mLOY when the boundary of the
two regions were <1Mbp apart. If significant associations were observed in con-
ditional analyses and adjacent loci were apart by >200 kbp but <1Mbp, we
regarded the two loci as different.
Conditional analysis. We applied conditional analyses to identify independent
signals in a single locus or adjacent loci. We incorporated dosages of a variant
whose effect we would like to condition on as a covariate in linear mixed model.
We applied the same threshold (P < 5.0 × 10−8) to the conditional analyses to
define significant associations.
Replication of the associations with the UKBB data. We obtained UKBB
association results of the 46 top variants in the BBJ. In the UKBB data, 205,011
male subjects were analyzed, and presence of mLOY was determined by hidden
Markov model together with phased B allele frequencies calculated by signal
intensity data of markers in pseudo autosomal region (PAR)1 of genotyping
arrays39. We compared risk allele between the two populations. We applied the
same MAF threshold of 0.005 as the BBJ to the UKBB. The four secondary signals
in the BBJ were not included, since top variants were different between the two
populations and statistics in conditional analyses with the use of the same con-
ditioned variants were not available.
Functional annotation using Haploreg. We analyzed overlap between lead var-
iants in significant loci associated with mLOY and enhancer marks in cells by
Haploreg (URL) to infer cell types important for mLOY. Briefly, enrichment of lead
SNPs for mLOY in enhancer histone marks in cell types was evaluated by com-
paring estimated overlap based on pruned variants in the 1000 Genomes Project
with minor allele frequencies >0.05 in any population. The enrichment significance
was computed by binomial test. Since Haploreg requires rs id of SNPs which is not
available for Chr2:136879065, we used rs6751768, which is in strong LD with
Chr2:136879065 (r2= 0.80), for this locus. A significant level of associations was
set based on Bonferroni’s correction.
Pathway analysis. We conducted pathway analysis with the use of the PASCAL
software35 (URL) which takes LD structure of nearby genes into consideration. To
avoid overestimation of GWAS significant variants, we calculated gene score for
pathway analysis by PASCAL by using the sum of statistics of variants in single
genes rather than the maximum of the statistics. Bonferroni’s correction
accounting for all of the pathways (REACTOME, KEGG, and BIOCARTA) was
used to set a threshold of statistically significant enrichment (P < 0.05/1077).
LD score regression to estimate confounding bias. To evaluate the polygenic
effect on mLOY and assess confounding bias leading to inflation of median chi-
square statistics, we used LD score regression analysis with the use of ldsc soft-
ware18. We regarded intercept in LD score regression <1.05 or ldsc ratio (an index
estimating confounding bias of GWAS statistics) <0.3 as no confounding bias18.
Partitioning heritability for cell groups and cell types. We evaluated enrichment
of heritability of histone marks in cell groups or detailed cell types in each cell
group by conditioning on the full baseline model described in Finucane et al.23 by
ldsc. Briefly, the full baseline model contains coding, intronic, UTR, promoter,
enhancer regions, histone marks, open-chromatin regions, and their extended
regions, none of which are specific to any cell types23. Although ldsc uses chi-
square statistics which are calculated from different distribution from that of bolt-
lmm44, we confirmed similar results of ldsc between bolt-lmm chi-square statistics
and normal linear regression chi-square statistics (with the same covariates as bolt-
lmm). Thus we showed results of analyses with the use of chi-square statistics in
bolt-lmm. We also applied to the analyses another full baseline model of ldsc
recently reported including information of LD-related annotations, synonymous,
and nonsynonymous annotations, ancient sequence age, and conserved function
across species24.
Genetic correlation. We also used ldsc software to assess genetic correlation45 of
mLOY and quantitative trait or malignancy susceptibility (Supplementary Note 4).
We used 44 blood tests out of the 58 quantitative traits we previously reported36
and whose summary statistics are available (JENGER, see URL). We used GWAS of
malignancy whose summary statistics are available in the BBJ36 (JENGER, see
URL). While samples were overlapped between traits, a genetic correlation esti-
mated by ldsc is shown not to be affected by sample overlap since sample overlap
does not change LD score45.
Mendelian randomization analysis. We conducted Mendelian randomization
analysis to assess causal relationship between mLOY and AST which showed a
significant genetic correlation with mLOY (Supplementary Note 4). We used a
Generalized Summary-data-based Mendelian Randomization approach
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implemented in GCTA software46 (bidirectional Mendelian randomization with
option –gsmr-direction 2).
Partitioning heritability with the use of ChIP seq data. We used the ChIP-seq
data in the previous report47. Raw human ChIP-seq data files in SRA format were
obtained from the GEO database and were converted to FASTQ format using the
fastq-dump function of SRA Toolkit. Each sequence read was aligned to the human
hg19 genome using Bowtie2 version 2.2.5 with default parameters. Peaks were
called using Model-based Analysis of ChIP-Seq (MACS) version 2.1 with default
settings (q < 0.01). Through this analysis, we obtained a total of 2856 ChIP seq data.
LD scores of transcription factor binding were constructed by extending 500 bp
from the peaks in ChIP seq. We conducted partitioning heritability of GWAS data
of mLOY by ChIP seq using ldsc. We first extracted 37 ChIP seq data, in which
HSC was analyzed for transcription factor binding based on the results of
enrichment analysis of significant variants in cell-specific enhancer marks and of
cell-type or group analyses of partitioning heritability. We partitioned heritability
of mLOY with the use of the LD scores of transcription factor bindings and the full
baseline model by Finucane et al.23. In addition, we also analyzed the data with the
use of the latest full baseline model described above.
LDSC-SEG. To evaluate the important cell types among the CD34+ cells, we used
LDSC-SEG48, a method recently developed to estimate heritability enrichment of
gene expression (or open chromatin) in various tissues and cell types by taking
advantage of tissue- and cell-specific eQTL data, which are available in the widest
range of tissues and cell types. We used data from Corces et al.26 who generated
ATAC-seq data of hematopoietic cell lineages, including CD34+ hematopoietic
stem progenitor cells. We computed Japanese LD scores of cell-specific gene
expression based on the ATAC-seq data by referring to European annotations for
the analyses (we obtained very similar results regardless of the origin of LD scores).
In this analysis, we used the full baseline model by Finucane et al.23 as baseline of
LD scores. In addition, we also analyzed the data with the use of the latest full
baseline model described above.
Survival data in the BBJ. The living status (dead or alive) of a total of 141,612 BBJ
subjects with one of 32 diseases was prospectively followed for more than 10 years
after DNA collection37. If a death was reported, a detailed search was conducted to
identify causes of death coded by ICD10 by accessing the national vital registration
system at the Japanese Ministry of Health, Labor, and Welfare. Further details are
written elsewhere37. We extracted cancers with >1000 deaths overall, and analyzed
lung, colon, esophagus, gastric, pancreas, hematologic and prostate/testis cancer as
specific malignancies. To analyze associations between mLOY and malignancy
mortality, we excluded subjects having had malignancy at registry, without infor-
mation of follow-up period or with follow-up <1 year to exclude potential
undiagnosed cancers and other fatal diseases. As a result, 54,887 subjects with
follow-up period of mean 8.0 years and standard deviation of 2.4 years remained
for the analyses. During the follow-up periods, 12,410 deaths were observed. We
used the survival package of R statistical software. We set subjects who did not die
during follow-up as controls and evaluated associations between mLOY and
mortality of overall or specific diseases. In addition to the use of mLRR-Y signals as
a quantitative trait, we used subjects with the lowest 3, 5, 10, and 20% of mLRR-Y
signals as categorical variables and compared with subjects whose mLRR-Y signals
not reaching the lowest 20%. The 20% cutoff was determined by the latest UKBB
mLOY study which reports 20% of male subjects in the UKBB were positive for
mLOY39. We used Cox proportional hazards regression for survival analysis to
estimate associations between mLOY and the cause of death adjusting for age at
DNA collection, data batches, disease status, and smoking.
Associations between mLOY and CBC data. We analyzed a total of 57,987 sub-
jects for associations between mLOY and CBC data for inference of biological
insights. We z-transformed CBC data to assess associations. Age, smoking, disease
status, and data set were used as covariates in the association study. To test the
hypothesis that subjects carrying high mLOY signals were strongly associated with
CBC data, we took subjects carrying top 1, 3, 5, and 10% of mLOY signal (i.e., those
with the lowest mean LRR of variants in chromosome Y). We divided all subjects in
this study into two groups (binary traits), with or without top 1, 3, 5, and 10% of
mLOY signals and associated the binary traits with the CBC data mentioned above
together with covariates of age, smoking, disease status, data set with the use of
logistic regression analysis.
URL. For 1000 Genomes Project, see http://www.1000genomes.org/; for GWAS
catalog, see https://www.ebi.ac.uk/gwas/; for LDSC and SEG-LDSC, see https://
github.com/bulik/ldsc/; for PASCAL, see https://www2.unil.ch/cbg/index.php?
title=Pascal; for Minimac, see https://genome.sph.umich.edu/wiki/Minimac; for
Haploreg, see https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php; for
JENGER, see http://jenger.riken.jp/en/; for R, see https://www.r-project.org/; for
Plink1.9, see https://www.cog-genomics.org/plink2; for bolt-lmm, see https://data.
broadinstitute.org/alkesgroup/BOLT-LMM/; for LCR, see ftp://ftp.1000genomes.
ebi.ac.uk/vol1/ftp/release/20130502/supporting/low_complexity_regions/hs37d5-
LCRs.20140224.bed.gz.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
GWAS summary statistics of mLOY in the BBJ is available at RIKEN website (http://
jenger.riken.jp/en/). While individual-level genetic data are not accessible, all other data
contained in the article and its supplementary information are available upon reasonable
request.
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